Novogene And Pacific Biosciences To Develop And Co-Market Applications Based On Sequel Platform

By Bio-IT World Staff

July 18, 2017 | Novogene and Pacific Biosciences of California have agreed to jointly develop and promote novel applications based on the PacBio Sequel System. New applications developed under this agreement are expected to focus on basic and translational research in the field of precision medicine, including methods for sample processing, workflow automation, algorithm development, and database construction.

Sequel Systems are based on Single Molecule, Real-Time (SMRT) technology, which has the advantage of uniform coverage across all genome regions, including palindromes and low-diversity regions of the genome. Genome sequencing with PacBio Systems helps provide more complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

With the ability to run up to 10 PacBio Sequel Systems, Novogene operates in a facility that has the largest capacity for SMRT Sequencing in a single location. As a leading genomic service provider with a comprehensive portfolio of service products, Novogene has extensive expertise in developing and marketing high-quality end-toend service solutions, from sample preparation to data analysis and interpretation, for a variety of applications in diverse research and clinical fields.